AccessibilityHelpAbout Us
BioLineRx logo

BioLineRx(NASDAQ) BLRX

Market Cap$12.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-98%
1 Year-29%
1 Month-4%
$2.56
-1.35%
-0.03Today
BioLineRx last closing stock price
MetricPriceDate
Last closeUSD 2.592026-09-08
BioLineRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.16%USD 2.762026-09-01
1 month-4.43%USD 2.712026-08-07
3 month-21.04%USD 3.282026-06-10
Year to date-6.5%USD 2.772025-12-31
1 year-28.85%USD 3.642025-09-08
3 year-96.9%USD 83.602023-09-08
5 year-97.63%USD 109.202021-09-09
Since inception-99.92%USD 3,354.002011-07-25

BioLineRx Financials at a Glance

Market Cap

$12.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.40M

Net Income (TTM)

-$8.03M

EPS (TTM)

-$1.82

P/E Ratio

-1.42

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$2.56

Volume

3,906.817

Open

$2.59

Previous Close

$2.59

Daily Range

$2.53 - $2.59

52-Week Range

$2.15 - $4.56

Estimated Earnings Date

Nov 23, 2026

BLRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioLineRx

BioLineRx Ltd. is an Israeli biopharmaceutical company focused on developing innovative therapies primarily in oncology. Established in 2003, the company is advancing its clinical-stage pipeline, which includes promising candidates for various cancers and other serious conditions.

Products and Services
  • Motixafortide: A peptide in Phase 2 studies for metastatic pancreatic adenocarcinoma
  • AGI-134: An immuno-oncology agent in Phase 1/2a trials for solid tumors
  • BL-5010: A proprietary device for non-surgical skin lesion removal
Growth Outlook
  • Motixafortide has completed pivotal Phase 3 trials, indicating strong potential for market entry
  • Strategic collaborations with MSD and MD Anderson enhance research capabilities and market reach
  • Ongoing studies for Motixafortide in COVID-19 related conditions may open new therapeutic avenues
Financial Highlights
  • Recent quarterly revenue of $477,000, showing growth from previous quarters
  • Cash and short-term investments totaled $17.35 million, providing operational flexibility
  • Net income for the latest quarter was -$2.59 million, reflecting ongoing investment in R&D
BioLineRx Ltd. is positioned in the biotechnology sector with a focus on oncology, leveraging its innovative pipeline to address significant medical needs. The company's lead product, Motixafortide, has shown promising results in clinical trials, which could lead to substantial market opportunities. Collaborations with established entities like MSD and MD Anderson Cancer Center further strengthen its research and development efforts. Financially, while the company is currently operating at a loss, it maintains a solid cash position that supports ongoing research initiatives. The growth potential, combined with strategic partnerships, makes BioLineRx an intriguing option for investors interested in the biotechnology field.
AI Generated • Aug 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Philip Adam Serlin, MBA, CPA

Website

www.biolinerx.com

Headquarters

Hevel Modi'in, HM 7177871, IL

BLRX Financials

Key Financial Metrics (TTM)

Gross Margin

69.88%

Operating Margin

-879.25%

Net Income Margin

-577.39%

Return on Equity

-47.22%

Return on Capital

-36.58%

Return on Assets

-24.17%

Earnings Yield

-70.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.85M

Volume

3.91K

Avg. Volume

20.50K

Financials (TTM)

Gross Profit

$976.26K

Operating Income

-$12.25M

EBITDA

-$8.26M

Operating Cash Flow

-$10.88M

Capital Expenditure

-$25.21K

Free Cash Flow

-$10.90M

Cash & ST Invst.

$13.08M

Total Debt

$7.94M

BioLineRx Performance Analysis

BioLineRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 4,787,631N/A
20242024-12-31USD 29,077,355507.3%
20252025-12-31USD 1,189,361-95.9%
BioLineRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3040.5%
Q42025-12-31-54.3%
Q12026-03-31144.4%
Q22026-06-30-37.3%
BioLineRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.27-21.4%
20232023-12-31USD -37.6595.4%
20242024-12-31USD -4.64-87.7%
20252025-12-31USD -0.29-93.7%
BioLineRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3077.9%
Q42025-12-31-44.9%
Q12026-03-31-81.7%
Q22026-06-30-20.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$299.05K

-1.6%

Gross Profit

$159.70K

-31.2%

Gross Margin

53.40%

N/A

Market Cap

$12.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$570.86K

N/A

Employees

22

N/A

Net Income

-$3.08M

+21.9%

EBITDA

-$3.56M

-1.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$13.08M

-53.6%

Total Debt

$7.94M

-37.0%

Accounts Receivable

$727.99K

+159.1%

Inventory

$2.17M

-24.0%

Long Term Debt

$3.18M

-58.8%

Short Term Debt

$4.76M

-2.6%

Return on Assets

-24.17%

N/A

Return on Invested Capital

-62.23%

N/A

Free Cash Flow

-$3.26M

-1739.2%

Operating Cash Flow

-$3.26M

-1742.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LNAILunai Bioworks Inc.
$2.66+2.31%
AIMDAinos, Inc.
$1.48-0.34%
ICUSeaStar Medical Holding Corporation
$3.04+3.05%
ADTXAditxt, Inc.
$0.01+1.92%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.24-0.05%
NOKNokia
$10.85+0.02%
INTCIntel
$105.07+0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.56+0.00%

Questions About BLRX

What is the current price of BioLineRx?

BioLineRx is trading at $2.56 per share.

What is the 52-week range for BioLineRx?

Over the past 52 weeks, BioLineRx has traded between $2.15 and $4.56.

How much debt does BioLineRx have?

As of the most recent reporting period, BioLineRx reported total debt of $7.94M.

How much cash does BioLineRx have on hand?

BioLineRx reported $4.63M in cash and cash equivalents in its most recent financial results.

What is BioLineRx’s dividend yield?

BioLineRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services